Eosinophils and Lung Cancer: From Bench to Bedside.
Anne SibilleJean-Louis CorhayRenaud LouisVincent NinaneGuy JerusalemBernard DuysinxPublished in: International journal of molecular sciences (2022)
Eosinophils are rare, multifunctional granulocytes. Their growth, survival, and tissue migration mainly depend on interleukin (IL)-5 in physiological conditions and on IL-5 and IL-33 in inflammatory conditions. Preclinical evidence supports an immunological role for eosinophils as innate immune cells and as agents of the adaptive immune response. In addition to these data, several reports show a link between the outcomes of patients treated with immune checkpoint inhibitors (ICI) for advanced cancers and blood eosinophilia. In this review, we present, in the context of non-small cell lung cancer (NSCLC), the biological properties of eosinophils and their roles in homeostatic and pathological conditions, with a focus on their pro- and anti-tumorigenic effects. We examine the possible explanations for blood eosinophilia during NSCLC treatment with ICI. In particular, we discuss the value of eosinophils as a potential prognostic and predictive biomarker, highlighting the need for stronger clinical data. Finally, we conclude with perspectives on clinical and translational research topics on this subject.
Keyphrases
- immune response
- small cell lung cancer
- electronic health record
- big data
- advanced non small cell lung cancer
- drug delivery
- oxidative stress
- type diabetes
- stem cells
- emergency department
- toll like receptor
- metabolic syndrome
- cancer therapy
- bone marrow
- climate change
- risk assessment
- young adults
- artificial intelligence
- combination therapy
- insulin resistance
- epidermal growth factor receptor
- drug induced
- replacement therapy